Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6025611 | 0.90 | BCL2L1 (0.35) | BCL2L1CA2CA4MEN1KMT2A | |
| SCHEMBL6533301 | 0.90 | BCL2L1 (0.36) | BCL2L1CA1CA2CA12CA4 | |
| SCHEMBL6025032 | 0.81 | KMT2A (0.41) | BCL2L1CA1CA12CA9MEN1 | |
| SCHEMBL6532196 | 0.74 | LMNA (0.39) | CA1CA2CA12MEN1KMT2A | |
| SCHEMBL6470754 | 0.72 | CA2 (0.45) | CA1CA2CA12CA9CA7 | |
| SCHEMBL6025517 | 0.71 | KMT2A (0.44) | BCL2L1CA1CA2CA9MEN1 | |
| SCHEMBL6530524 | 0.65 | KMT2A (0.41) | BCL2L1CA1CA2CA12CA9 | |
| SCHEMBL6530534 | 0.64 | PTGES2 (0.39) | CA1CA2CA12CA9CA7 | |
| SCHEMBL6026281 | 0.63 | KMT2A (0.42) | BCL2L1CA1CA2CA9MEN1 | |
| SCHEMBL6531283 | 0.62 | KMT2A (0.41) | BCL2L1CA1CA2CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109535155-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-3080132-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015085925-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| EP-1685119-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005049593-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049594-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |